Asian Journal of Pharmaceutical Research
Year : 2021, Volume : 11, Issue : 4
First page : ( 247) Last page : ( 250)
Print ISSN : 2231-5683. Online ISSN : 2231-5691.
Article DOI : 10.52711/2231-5691.2021.00043

Relugolix is the first and currently only orally-administered gnrh receptor antagonist approved for the treatment of prostate cancer: A review

Bavaskar Sunil R. Mr.^*, Bhurat Mayur R. Mr.

Shri. Prakashchand Jain College of Pharmacy and Research, Palaskhede, JamnerMaharashtraIndia

^*Corresponding Author E-mail: bavaskarsunilkumar@gmail.com

Online published on 8 July, 2022.

Abstract

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States’ FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer-similar therapies such as degarelix require subcutaneous administration-and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals.In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to leuprolide, another androgen deprivation therapy used in the treatment of prostate cancer^1,2

Top

Keywords

Relugolix, Gonadotropin-releasing hormone (GnRH) receptor, Prostate cancer.

Top